Objective: To evaluate the utility of Golgi protein 73 (GP73) in the diagnosis of non-alcoholic steatohepatitis (NASH) and hepatic fibrosis (HF) staging. Methods: Ninety-one patients with non-alcoholic fatty liver disease (NAFLD) were allocated to NAFL (n = 46) and NASH (n = 45) groups according to their NAFLD activity score (NAS), and there were 30 healthy controls. Serum GP73 was measured by ELISA, GP73 protein expression was evaluated using immunohistochemistry, and FibroScan was used to determine liver hardness. Results: The serum GP73 concentrations of the NAFL and NASH groups were significantly higher than those of controls. GP73 expression in the liver of the patients gradually progressed from absent or low to moderate or high. Serum GP73 positively correlated with liver expression, and the serum and liver GP73 of the patients positively correlated with FibroScan value and HF stage. There was a strong positive correlation of the combination of alanine aminotransferase, gamma glutamyl transferase and GP73 with NASH. The combination of serum GP73 and FibroScan value was found to predict NASH (NAS > 4) and advanced HF (stage ≥2) in patients with NAFLD using receiver operating characteristic analysis. Conclusion: Serum GP73 may be useful in the diagnosis of NASH and the staging of HF.
CITATION STYLE
Li, Y., Yang, Y., Li, Y., Zhang, P., Ge, G., Jin, J., … Sheng, H. (2021). Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis. Journal of International Medical Research, 49(11). https://doi.org/10.1177/03000605211055378
Mendeley helps you to discover research relevant for your work.